U.S. Markets close in 5 hrs 48 mins

OncoGenex Pharmaceuticals, Inc. (OGXI)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.354-0.01 (-2.08%)
As of 10:02AM EDT. Market open.
People also watch
THLDONTXRPRXOPXACYCC
Interactive chart
Previous Close0.361
Open0.351
Bid0.350 x 3400
Ask0.360 x 1200
Day's Range0.350 - 0.360
52 Week Range0.330 - 1.320
Volume39,459
Avg. Volume159,617
Market Cap10.64M
Beta2.93
PE Ratio (TTM)-0.54
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cubelast month

    ETFs with exposure to OncoGenex Pharmaceuticals, Inc. : April 19, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to OncoGenex Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to OGXI-US. Comparing the performance and risk of OncoGenex Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube2 months ago

    ETFs with exposure to OncoGenex Pharmaceuticals, Inc. : April 5, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to OncoGenex Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to OGXI-US. Comparing the performance and risk of OncoGenex Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • OncoGenex Pharmaceuticals, Inc. :OGXI-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017
    Capital Cube2 months ago

    OncoGenex Pharmaceuticals, Inc. :OGXI-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017

    Categories: Yahoo Finance Get free summary analysis OncoGenex Pharmaceuticals, Inc. reports financial results for the year ended December 31, 2016. We analyze the earnings along side the following peers of OncoGenex Pharmaceuticals, Inc. – Immunomedics, Inc., Exelixis, Inc., Celgene Corporation, Ionis Pharmaceuticals, Inc., Bovie Medical Corporation, Teva Pharmaceutical Industries Limited Sponsored ADR, Eli Lilly and Company and Seattle ... Read more (Read more...)